VALEANT PHARMACEUTICALS INTL I (VRX) Fundamental Analysis & Valuation
NYSE:VRX • CA91911K1021
23.4
-0.83 (-3.43%)
At close: Jul 13, 2018
23.36
-0.04 (-0.17%)
After Hours: 7/13/2018, 8:04:05 PM
This VRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
No Fundamental Analysis report for VRX not available.
VRX Fundamentals: All Metrics, Ratios and Statistics
23.4
-0.83 (-3.43%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.13%
Inst Owner Change-27.49%
Ins Owners1.27%
Ins Owner Change0%
Market Cap8.16B
Revenue(TTM)8.61B
Net Income(TTM)-917.00M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.91 | ||
| Fwd PE | 6.74 | ||
| P/S | 0.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.8 | ||
| P/tB | N/A | ||
| EV/EBITDA | 45.74 |
EPS(TTM)3.96
EY16.92%
EPS(NY)3.47
Fwd EY14.83%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS24.69
BVpS12.97
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.56% | ||
| ROE | -20.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -10.65% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.59 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -0.29 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.98%
EPS 3YN/A
EPS 5Y-8.55%
EPS Q2Q%-68.21%
EPS Next Y-12.27%
EPS Next 2Y-4.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.51%
Revenue growth 3YN/A
Revenue growth 5Y8.34%
Sales Q2Q%-5.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
VALEANT PHARMACEUTICALS INTL I / VRX FAQ
What is the fundamental rating for VRX stock?
ChartMill assigns a fundamental rating of 3 / 10 to VRX.
Can you provide the valuation status for VALEANT PHARMACEUTICALS INTL I?
ChartMill assigns a valuation rating of 6 / 10 to VALEANT PHARMACEUTICALS INTL I (VRX). This can be considered as Fairly Valued.
What is the profitability of VRX stock?
VALEANT PHARMACEUTICALS INTL I (VRX) has a profitability rating of 5 / 10.
Can you provide the financial health for VRX stock?
The financial health rating of VALEANT PHARMACEUTICALS INTL I (VRX) is 1 / 10.
Can you provide the expected EPS growth for VRX stock?
The Earnings per Share (EPS) of VALEANT PHARMACEUTICALS INTL I (VRX) is expected to decline by -12.27% in the next year.